3 Crucial Things I'll Be Looking for in Moderna's Earnings Report
Moderna's (NASDAQ: MRNA) earnings reports have been giving investors reason to celebrate. Earlier this year, the coronavirus vaccine giant generated more than $1 billion in revenue and profit after just one full quarter of commercialization.
On Thursday, Moderna will report earnings for the third quarter -- and expectations remain high. After all, Moderna already predicted $20 billion in coronavirus vaccine sales for the year. But there will be a lot more to the biotech's quarterly earnings report than vaccine sales. Here are three specific points to look for -- ones that may be critical for Moderna's future.
Image source: Getty Images.
Source Fool.com
